Optimizing Testing in The Laboratory with A Special Focus on Antibody Validation
Activity Description:
This interactive microlearning activity is part of a case-based series designed to engage pathologists, laboratory professionals, and other members of the multidisciplinary cancer care team in improving biomarker testing and treatment for NSCLC. This specific course focuses on exploring emerging biomarkers and antibody validation methods.
Course topics include:
HER2 in NSCLC
Antibody validation methods
Reducing risk in antibody validation and biomarker testing
Target Audience
This activity has been designed to meet the educational needs of pathologists and laboratory professionals.
Faculty/Authors
Jefree Schulte Director of Surgical Pathology Assistant Professor (CHS) University of Wisconsin, Madison, WI
Physician Competencies: Patient Care, Medical Knowledge, Practice-Based Learning, and Improvement
Credit Designation Statement The ASCP designates this activity for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ASCP designates this activity for a maximum of .25 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT.
Method of ParticipationTo complete the activity and receive credit, the participant must attend the program. CME certificates will be provided online.
Commercial Support This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.
Instructions
To claim CME/CMLE credit for the exercise, do the following:
Upon completion of this activity, you will be able
Explore the emerging biomarker, HER2, in NSCLC and its implications for the laboratory
Develop sound antibody validation methods
Discuss strategies to reduce risk in antibody validation and biomarker testing